DCAT: Value Chain Insights — Industry Perspectives: Low-Volume Drugs and Manufacturing

Rising numbers of orphan drugs and targeted therapies need to be manufactured in small volumes. How can pharma companies and CDMOs manufacture these economically? Read the article to gain insights from Recro’s Richard Sidwell, Ph.D., Brittany L. Hayes, Ph.D., and others.

Want to know more?

Read the article

Back to Thought Leadership